Combining censored and uncensored data in a U-statistic: Design and sample size implications for cell therapy research

International Journal of Biostatistics

Volumn 7, Issue 1, 2011, Pages

  Moyé, Lemuel A ^a   Lai, Dejian ^b   Jing, Kaiyan ^b   Baraniuk, Mary Sarah ^b   Kwak, Minjung ^c   Penn, Marc S ^d   Wu, Colon O ^c  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

Author keywords

clinical trials; score function; stem cells; U statistic

Indexed keywords

ARTICLE; CELL THERAPY; CENSORED DATA; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); LIFE EVENT; METHODOLOGY; MORTALITY; SAMPLE SIZE; SIGNIFICANT CLINICAL EVENT; STATISTICAL ANALYSIS; STATISTICAL CONCEPTS; STATISTICAL PARAMETERS; STATISTICS; U STATISTIC; UNCENSORED DATA;

BIOSTATISTICS; CLINICAL TRIALS, PHASE II AS TOPIC; ENDPOINT DETERMINATION; HUMANS; RESEARCH DESIGN; SAMPLE SIZE; STATISTICS, NONPARAMETRIC; STEM CELL RESEARCH;

EID: 79961230913     PISSN: None     EISSN: 15574679     Source Type: Journal    
DOI: 10.2202/1557-4679.1286     Document Type: Article

References (42)

1. Abdel-Latif A, et al.(2007) Adult bone marrow-derived cells for cardiac repair. Arch Intern Med. (2007). 167:989-997.
2. Assmus B, et al. (2002) Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation 2002;106:3009-3017. (Pubitemid 35440281)
3. Balsam LB, et al. (2004) Haematopoietic stem cells adopt mature haematopoietic fates in ischemic myocardium. Nature 2004;428:668-673. (Pubitemid 38524811)
4. Follmann D and Wu M. (1995) An approximate generalized linear model with random effects for informative missing data. Biometrics. 1995 Mar;51(1):151-68.
5. Ford ES, et al. (2007) Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med 2007;356:2388-98. (Pubitemid 46883773)
6. Gehan EA. (1965) "A generalized Score test for comparing arbitrarily singly-censored samples". Biometrika, 52 203-223 (1965).
7. Genz A, Bretz F, Miwa T, I X, Leisch F, Scheipl F, Bornkamp B, Hothorn T (2011). Mvtnorm: multivariate normal and t distributions. R package version 0.9-96. URL http://CRAN.R-project.org/package=mvtnorm.
8. Grothues F, Smith GC, Moon JC, Bellenger NG, Collins P, Klein HU, Pennel DJ. (2002) Comparison of Interstudy Reproducibility of Cardiovascular Mangetic Resonance With Two-Dimensional Echocardiography in Normal Subjects and in Subjects With Heart Failure or Left Ventricular Hypertrophy. Am J Cardiol; 90: 29-34. (Pubitemid 34671198)
9. Hothorn T, Bretz F,Westfall P (2008). Simultaneous Inference in General Parametric Models. Biometrical Journal 50(3), 346-363.
10. Jackson KA, et al.(2001) Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. J Clin Invest 2001;107:1395-1402. (Pubitemid 32522033)
11. Janssens S, et al.(2006) Autologous bone marrow-derived stemcell transfer in subjects with ST-segment elevation myocardial infarction: doubleblind, randomised controlled trial. Lancet 2006;367:113-121. (Pubitemid 43077127)
12. Kocher AA, et al. (2001) Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 2001;7:430-436. (Pubitemid 32298545)
13. Kowalski J and Tu XM. (2007) Modern Applied U-statistics. New York. Wiley. 2007.
14. Lachin J. (1999) Worst-rank score analysis with informatively missing observations in clinical trials. Controlled Clinical Trials 1999; 20:408-422. (Pubitemid 29460918)
15. Levy D, et al. (2002) Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002;347:1397-402. (Pubitemid 35239711)
16. Lunde K, et al.(2006) Intracoronary injection of mononuclear bone marrow cells in acute wall infarction. NEJM 2006;355:1199-1209. (Pubitemid 44427444)
17. Mann B. and Whitney DR (1947): On a test of whether one of two random variables is stochastically larger than the other. Annals of Mathematical Statistics, 18:50-60.
18. Moyé LA, et al. (1992) Analysis of a Clinical Trial Involving a Combined Mortality and Adherence Dependent Interval Censored Endpoint. Statistics in Medicine. Vol. 11, 1705-1717 (1992).
19. Moyé LA for the SAVE Cooperative Group (1991) Rationale and Design of a Trial to Assess Subject Survival and Ventricular Enlargement after Myocardial Infarction. Am J Cardiol 1991;68:70D-79D.
20. Murry CE, et al. (2004) Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature 2004;428:664-668. (Pubitemid 38524810)
21. National Institute of Neurological Disorders and Stroke rt- PA Stroke Study Group. (1995). Tissue plasminogen activator for acute ischemic stroke. New England Journal of Medicine 333, 1581-1587.
22. O'Brien PC. (1984) Procedures for Comparing Samples with Multiple Endpoints Biometrics,1984;40; 1079-1087.
23. Orlic D, et al. (2001) Bone marrow cells regenerate infracted myocardium. Nature 2001;410:701-705. (Pubitemid 32290358)
24. Penicka M, et al. (2007) Research Correspondence: Intracornonary injection of autologous bone marrow-derived mononuclear cells in subjects with large anterior acute myocardial infarction: A prematurely terminated randomized study. Journal of the American College of Cardiology.49:2373-2374. (Pubitemid 46891709)
25. Pfeffer MA, et al. (1992) Effect of Captopril on mortality and morbidity in subjects with left ventricular dysfunction after myocardial infarction - results of the Survival and Ventricular Enlargement Trial. N Eng J Med 327(10):669-677, Sep 3, 1992.
26. Roger VL, et al. (2004) Trends in heart failure incidence and survival in a community-based population. JAMA 2004;292:344-50. (Pubitemid 38944258)
27. Rosamond W, et al. (2007) Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007;115:e69-171.
28. Schächinger V, et al. (2006) Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. NEJM 2006;355:1210-1221. (Pubitemid 44427445)
29. Strauer BE, et al. (2002) Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 2002;106:1913-1918. (Pubitemid 35176294)
30. Tan M, Fang HB, Tian GL, Houghton PJ. Small sample inference for incomplete longitudinal data with truncation and censoring in tumor xenograft models. Biometrics 2002; 58:612-620. (Pubitemid 35001479)
31. Tang DI, et al. (1989a) An approximate likelihood ratio test for a normal mean vector with nonnegative components with application to clinical trials. Biometrika 76, 577-583.
32. Tang DI, et al. (1989b) Design of group sequential clinical trials with multiple endpoints. Journal of the American Statistical Association 84, 776-779.
33. Tang DI, et al. (1993) On the design and analysis of randomized clinical trials with multiple endpoints. Biometrics 49, 23-30.
34. Tang DI and Getter NL. (1999) Closed Testing Procedures for Group Sequential Clinical Trials with Multiple Endpoints Biometrics, 55; 1188-1192.
35. Tilley BC, et al. (1996) Use of a global test for multiple outcomes in stroke trials with application to the National Institute of Neurological Disorders and Stroke t-PA stroke trial. Stroke 27, 2136-2142. (Pubitemid 26372593)
36. Traverse JH, Henry TD, Vaughan D, Ellis SG, Pepine CJ, Willerson JT, Zhao DXM, Piller LB, Penn MS, Byrne BJ, Perin EC, Gee AP, Hatzopoulous AK, McKenna DH, Forder JR, Taylor DA, Cogle CR, Olson RE, Jorgenson BC, Sayre SL, Vojvodic RW, Gordon DJ, Skarlatos SI, Moyé LA, Simari RD for the Cardiovascular Cell Therapy Research Network. Rationale and Design for TIME: A Phase-II, Randomized, Double-Blind, Placebo-Controlled Pilot Trial Evaluating the Safety and Effect of Timing of Administration of Bone Marrow Mononuclear Cells Following Acute Myocardial Infarction. American Heart Journal:158:356-63.
37. Traverse JH, Henry TD, Vaughan D, Ellis SG, Pepine CJ, Willerson JT, Zhao DXM, Piller LB, Penn MS, Byrne BJ, Perin EC, Gee AP, Hatzopoulous AK, McKenna DH, Forder JR, Taylor DA, Cogle CR, Olson RE, Jorgenson BC, Sayre SL, Vojvodic RW, Gordon DJ, Skarlatos SI, Moyé LA, Simari RD for the Cardiovascular Cell Therapy Research Network. Rationale and Design for TIME: A Phase-II, Randomized, Double-Blind, Placebo-Controlled Pilot Trial Evaluating the Safety and Effect of Timing of Administration of Bone Marrow Mononuclear Cells Following Acute Myocardial Infarction. American Heart Journal:158:356-63.
38. Willerson JT, Perin EC, Ellis SG, Pepine CJ, Henry TD, Zhao DX, Lai D, Penn MS, Byrne BJ, Silva G, Gee A, Traverse JH, Hatzopoulos AK, Forder JR, Martin D, Kronenberg M, Taylor DA, Cogle CR, Baraniuk S, Westbrook L, Sayre SL, Vojvodic RW, Gordon DJ, Skarlatos SI, Moyé LA, Simari RD; Cardiovascular Cell Therapy Research Network (CCTRN).Intramyocardial injection of autologous bone marrow mononuclear cells for subjects with chronic ischemic heart disease and left ventricular dysfunction (First Mononuclear Cells injected in the US [FOCUS]): Rationale and design.Am Heart J. 2010 Aug;160(2):215-23.
39. Wittkowski KM, et al. (2004) Combining several ordinal measures in clinical studies. Statistics in Medicine. Vol. 23, 1579-1592 (2004). (Pubitemid 38660410)
40. Wollert KC, et al.(2004) Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomized controlled clinical trial. Lancet 2004;364:141-148. (Pubitemid 38891685)
41. Wu JR, Houghton PJ (2010) Interval approach to assessing antitumor activity for tumor xenograft studies. Pharmaceutical Statistics 9;1:46-54.
42. Yoon YS, et al. (2005) Clonally expanded novel multipotent stem cells from human bone marrow regenerate myocardium after myocardial infarction. JCI 2005;115:326-338.